ITV-1 – ImmunH is a drug compound for treatment HIV-1 infection AIDS and Hepatitis . However, based on preclinical binding data, anecdotal clinical data, and early results from the South African immunology studies indicating an apparent Th1 immune mechanism, the compound holds promise for several infectious diseases, chronic infections and hepatitis for which enhanced cell-mediated immunity would be beneficial.
DOSAGE AND ADMINISTRATION
ITV-1 – ImmunH is presented in the form of 16 injections, which are administrated biweekly on consecutive days for eight weeks using an intramuscular method. Before injection, the vial must be shaken and temperate to ambient temperature.
CONTRAINDICATIONS AND DRUG INTERACTIONS
ITV-1 – ImmunH can not be used with other vaccines or other protein containing treatments.
ITV-1 – ImmunH can not be used in parallel with any immunosuppresive drugs.
SIDE EFFECTS AND OVER DOSAGE
Some patients have demonstrated mild flue like symptoms with occasional low-grade fever, malaise and arthralgias.
Animal safety studies have demonstrated no toxic effects.
At testing on people in a clinical trial of 32 injections on each patient, has been shown: complete lack of side effects, good tolerance in all patients, improvement of the immune status, decrease in the viral load, a good treatment effect on opportunistic infections, very good compatibility with all of the other modern antiretroviral drugs.
ITV-1 – ImmunH appear to be safe and does not impair the ability of people to operate machinery.